X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AJANTA PHARMA - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AJANTA PHARMA IPCA LABS/
AJANTA PHARMA
 
P/E (TTM) x 30.9 23.0 134.8% View Chart
P/BV x 4.6 4.4 103.4% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   AJANTA PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-18
AJANTA PHARMA
Mar-18
IPCA LABS/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs6951,818 38.3%   
Low Rs4001,106 36.2%   
Sales per share (Unadj.) Rs260.2239.5 108.7%  
Earnings per share (Unadj.) Rs19.052.8 35.9%  
Cash flow per share (Unadj.) Rs33.159.5 55.5%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.0230.0 92.6%  
Shares outstanding (eoy) m126.2088.77 142.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.16.1 34.5%   
Avg P/E ratio x28.927.7 104.2%  
P/CF ratio (eoy) x16.624.6 67.4%  
Price / Book Value ratio x2.66.4 40.4%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,120129,782 53.3%   
No. of employees `00013.36.8 195.1%   
Total wages/salary Rs m7,3593,765 195.5%   
Avg. sales/employee Rs Th2,477.43,128.4 79.2%   
Avg. wages/employee Rs Th555.2554.0 100.2%   
Avg. net profit/employee Rs Th180.6689.7 26.2%   
INCOME DATA
Net Sales Rs m32,83621,258 154.5%  
Other income Rs m418242 173.0%   
Total revenues Rs m33,25421,499 154.7%   
Gross profit Rs m4,5056,584 68.4%  
Depreciation Rs m1,777596 298.3%   
Interest Rs m2404 5,858.5%   
Profit before tax Rs m2,9056,226 46.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5111,539 33.2%   
Profit after tax Rs m2,3944,686 51.1%  
Gross profit margin %13.731.0 44.3%  
Effective tax rate %17.624.7 71.2%   
Net profit margin %7.322.0 33.1%  
BALANCE SHEET DATA
Current assets Rs m19,45512,236 159.0%   
Current liabilities Rs m10,0763,461 291.2%   
Net working cap to sales %28.641.3 69.2%  
Current ratio x1.93.5 54.6%  
Inventory Days Days9860 162.6%  
Debtors Days Days6784 79.2%  
Net fixed assets Rs m20,26011,140 181.9%   
Share capital Rs m252177 142.7%   
"Free" reserves Rs m26,63320,237 131.6%   
Net worth Rs m26,88620,414 131.7%   
Long term debt Rs m2,34010 23,169.3%   
Total assets Rs m41,17324,486 168.1%  
Interest coverage x13.11,519.4 0.9%   
Debt to equity ratio x0.10 17,591.9%  
Sales to assets ratio x0.80.9 91.9%   
Return on assets %6.419.2 33.4%  
Return on equity %8.923.0 38.8%  
Return on capital %10.830.5 35.3%  
Exports to sales %47.60-   
Imports to sales %14.90-   
Exports (fob) Rs m15,642NA-   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,64211,667 134.1%   
Fx outflow Rs m4,8841,616 302.3%   
Net fx Rs m10,75910,052 107.0%   
CASH FLOW
From Operations Rs m3,4112,854 119.5%  
From Investments Rs m-1,354-2,604 52.0%  
From Financial Activity Rs m-1,304-2 65,205.0%  
Net Cashflow Rs m753248 303.6%  

Share Holding

Indian Promoters % 45.9 73.8 62.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 1.6 735.5%  
FIIs % 25.3 7.6 332.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 17.0 102.4%  
Shareholders   36,892 20,968 175.9%  
Pledged promoter(s) holding % 2.1 4.4 48.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NOVARTIS  TORRENT PHARMA  FRESENIUS KABI ONCO.  WYETH LTD  ABBOTT INDIA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Lower; Banking and Automobile Stocks Witness Selling(Closing)

After opening the day on a strong note, Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

3 Indian Stocks with Amazon-Like Potential(Profit Hunter)

Apr 10, 2019

We have identified 3 stocks with huge wealth building potential which meet our 'Click of a Button' criteria.

This Company is Making a Big Comeback and You Can Now Profit from Its Example(The 5 Minute Wrapup)

Apr 10, 2019

How Dell got its mojo back.

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

A Simple 3-Point Investing Manifesto for You the Indian Investor(The 5 Minute Wrapup)

Apr 11, 2019

A must have checklist for every investor in the Indian stock market.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 23, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS